New Platform Tests Pulmonary and Nasal Drug Products

A testing platform will help companies to test pulmonary and nasal drug products and their delivery devices.

The market for inhalable delivery is one of the fastest-growing areas of the drug delivery market, according to recent data published by Freedonia, an international business research company. Methods will grow by 9% per year through to 2012. The market is being driven by the increasing incidence of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Companies may not have a proven device selection process in place and may not have validated laboratory methods or instruments required to test the drug product and the device. Any misstep along the way runs the risk of costly project delays.

West Analytical Services (Lionville, PA; USA), a division of West Pharma Services, introduced the new testing platform, which encompass early-stage development, clinical development, and post-product launch stages. The service covers chemistry, manufacturing, and control (CMC) testing of nasal sprays, oral sprays, metered dose inhaler (MDI), dry powder inhaler (DPI), and nebulizers. The nasal and pulmonary product testing will be conducted at West's laboratory in Lionville.

Ms. Fran DeGrazio, West's vice president for marketing and strategy, said, "moving pulmonary and nasal drug products from early-stage development to the market is challenging for medical device, pharmaceutic, and biopharmaceutic companies.”


Related Links:
Freedonia
West Analytical Services